US Exclusive-Tens of millions of J&J COVID-19 shots sit at Baltimore factory -sources
Michigan cat becomes first pet in state to test positive for virus that causes COVID-19
Ingham County cat tested positive for virus that causes COVID-19. Its owners were confirmed to have COVID-19 about a week before the cat became ill.The cat had close contact with its owners, who were confirmed to have COVID-19 about a week before the feline became ill, the Michigan Department of Agriculture and Rural Development said in a release Tuesday. The cat was tested after it began to sneeze and has recovered.
By Carl O'Donnell
(Reuters) - An estimated 30 million to 50 million doses of Johnson & Johnson's COVID-19 vaccine made early this year sits idle in Emergent BioSolutions Inc's plant in Baltimore awaiting a green light from U.S. regulators to ship, two sources familiar with the matter said.
Emergent, a contract drug manufacturer, is waiting for the U.S. Food and Drug Administration to approve release of those doses. The agency must still inspect and authorize the plant before Emergent can ship newly manufactured drug substance, one of the sources said.
AP FACT CHECK: Biden overstates his record on COVID vaccine
WASHINGTON (AP) — President Joe Biden botched the numbers behind the COVID-19 vaccine rollout Thursday as he stretched to take all the credit for the surge of shots once he was in office. A look at his remarks during a CNN town hall event: BIDEN: “When I first was elected, there were only 2 million people who had COVID shots in the United States of America — and the vaccine. Now we got 190 million, because I went out and bought everything I could do and buy in sight and it worked." © Provided by Associated Press President Joe Biden greets people during a break as he participates in a CNN town hall at the Baltimore Center Stage Pearlstone Theater, Thursday, Oct.
The exact number of doses sitting idle cannot be determined, the source said, because Emergent only makes raw vaccine substance and does not fill vials with finished product.
The FDA in April halted operations at Emergent's production facility after J&J's vaccine was found to be contaminated with material from AstraZeneca's COVID-19 shots, which were also being manufactured there at the time.
The contamination ruined about 15 million J&J doses and set back its U.S. vaccine rollout by weeks.
Material manufactured for the J&J vaccine at the Baltimore plant prior to the April shutdown and awaiting FDA approval could be enough to produce as many as 50 million shots, the two sources said. They asked not to be named because they were not authorized to speak publicly on the issue.
Fantasy Football Week 7 prep: Starts, Sits, Sleepers, Busts for every game on the slate
Fantasy lineup calls -- as chosen by you -- for Week 7EAST RUTHERFORD, NEW JERSEY - OCTOBER 11: (NEW YORK DAILIES OUT) Chase Edmonds #29 of the Arizona Cardinals in action against the New York Jets at MetLife Stadium on October 11, 2020 in East Rutherford, New Jersey. The Cardinals defeated the Jets 30-10.
Of the 100 million doses worth of vaccine material Emergent described in an April Congressional hearing as being sidelined, the FDA has so far cleared nine batches of J&J's vaccine and three batches of AstraZeneca's. It has not disclosed how many doses were in those batches.
Emergent in late July said it would resume production of J&J's vaccine at the plant following additional FDA reviews, but has not provided updates on production or timing of potential shipments. [L1N2P535Q]
Emergent has begun making new vaccine substance, but the FDA has yet to provide guidance on when it plans to inspect the Baltimore facility, one of the sources said.
The FDA said in a statement that it conducted a limited inspection of Emergent's facility in July to confirm it had conducted corrective actions following the April production pause. A previous inspection had turned up a raft of sanitary, safety and bad manufacturing practice issues at the plant.
Fact check: Supply chain delays not related to COVID-19 vaccine mandates
Experts say vaccine mandates are not responsible for the current nationwide shipping delays. "The online claim is too strong," John Macdonald, associate professor of supply chain management and logistics at Colorado State University, said in an email. "Drivers from companies I contacted have had no challenges fulfilling their job duties due to vaccination status." USA TODAY reached out to Todd and the Facebook user who shared the post for comment.
The agency said it has not yet authorized the facility to ship doses and continues to review batches made prior to the production halt. It has based its batch approvals on reviews of facility records and quality testing conducted by the manufacturer.
The FDA typically waits for a drug manufacturing facility to produce multiple batches of its product before conducting an inspection, according to a former FDA official who asked not to be named because she was not authorized to speak with the media.
Following the Emergent plant shutdown, J&J lowered its production target for 2021 to between 500 million and 600 million doses from around 1 billion. It expects to be able to make 1 billion doses annually starting next year.
J&J has not specified whether it needs Emergent to restart production to hit its 2022 target. It has another manufacturing facility in Leiden, Netherlands, and production agreements with other contract manufacturers, including Catalent Inc and India's Biological E.
The United States contracted with J&J for 100 million shots in 2020 and ordered an additional 100 million in March.
Last week, the FDA authorized J&J's vaccine as a booster for people who are already vaccinated but desire additional protection against COVID-19, including anyone over age 18 who originally received the company's single-dose shot.
Use of J&J's vaccine fell sharply in the United States after it was linked to a rare but potentially lethal blood clotting disorder.
(Reporting by Carl O'Donnell; Editing by Caroline Humer and Bill Berkrot)
Baltimore Ravens vs. Minnesota Vikings NFL Week 9 Odds, Plays and Insights .
Check out odds, plays and more for the Baltimore Ravens vs. Minnesota Vikings NFL Week 9 matchup on November 7, 2021. © Provided by Sports Illustrated Oct 24, 2021; Baltimore, Maryland, USA; Cincinnati Bengals defensive end Sam Hubbard (94) hits Baltimore Ravens quarterback Lamar Jackson (8) during the second half at M&T Bank Stadium. Mandatory Credit: Tommy Gilligan-USA TODAY Sports The Baltimore Ravens (5-2) are 6-point favorites heading into their matchup on Sunday, November 7, 2021 against the Minnesota Vikings (3-4). The contest has a point total set at 49.5.